PARIS (Reuters) – French drugmaker Sanofi (NASDAQ:) SA has agreed to buy U.S. biopharmaceutical company Kadmon Holdings (NASDAQ:) Inc in a $1.9 billion deal, the companies said on Wednesday.
Sanofi said it has offered $9.50 per share in cash for Kadmon, representing a total equity value of approximately $1.9 billion on a fully diluted basis, and that both companies’ boards unanimously approved the transaction.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Need Your Help Today. Your $1 can change life.